NASDAQ:RYTMRhythm Pharmaceuticals Stock Price, Forecast & News

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RYTM stock has increased by 35.8% and is now trading at $20.37. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its earnings results on Monday, May, 4th. The company reported ($0.78) EPS for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.02. View Rhythm Pharmaceuticals' earnings history.

7 brokers have issued twelve-month target prices for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $34.29 in the next year. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for Rhythm Pharmaceuticals.

Media stories about RYTM stock have trended neutral this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutRhythm Pharmaceuticals.

Rhythm Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,440,000 shares, a decrease of 16.3% from the April 30th total of 1,720,000 shares. Based on an average trading volume of 246,300 shares, the short-interest ratio is currently 5.8 days. Currently, 4.3% of the shares of the stock are short sold. View Rhythm Pharmaceuticals' Current Options Chain.

Some companies that are related to Rhythm Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Arena Pharmaceuticals (ARNA), Allakos (ALLK), PTC Therapeutics (PTCT), Deciphera Pharmaceuticals (DCPH), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Axsome Therapeutics (AXSM), Uniqure (QURE), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX) and Intercept Pharmaceuticals (ICPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Agile Therapeutics (AGRX), Amarin (AMRN), Intra-Cellular Therapies (ITCI), Exelixis (EXEL), Nabriva Therapeutics (NBRV), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB) and Sangamo Therapeutics (SGMO).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.80%), Primecap Management Co. CA (8.03%), Wellington Management Group LLP (6.05%), BlackRock Inc. (5.67%), Federated Hermes Inc. (5.14%) and State Street Corp (2.22%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan and Todd Foley. View institutional ownership trends for Rhythm Pharmaceuticals.

RYTM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Deutsche Bank AG, Wells Fargo & Company MN, SG Americas Securities LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, and Todd Foley. View insider buying and selling activity for Rhythm Pharmaceuticals.

RYTM stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Rock Springs Capital Management LP, Aviva PLC, Federated Hermes Inc., Martingale Asset Management L P, Geode Capital Management LLC, State Street Corp, and Bessemer Group Inc.. View insider buying and selling activity for Rhythm Pharmaceuticals.

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RYTM stock can currently be purchased for approximately $20.37.

Rhythm Pharmaceuticals has a market capitalization of $898.11 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]